InteractionsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e865 (Published 08 February 2012) Cite this as: BMJ 2012;344:e865
- Robin Ferner, director, West Midlands Centre for Adverse Drug Reactions, Birmingham City Hospital, Birmingham B18 7QH, UK
Perhaps interactions between drugs are like interactions between people: mostly inconsequential, occasionally beneficial, sometimes deadly. The principle of cancer chemotherapy before monoclonal antibodies was that the benefits of different anticancer drugs would add up, and their harmful effects would differ. This gave us CHOP and MOPP, FOLFOX, and VAMP. The principle could be extended to antihypertensive medicines (Am J Med 2009;122:290-300, doi:10.1016/j.amjmed.2008.09.038), so we may yet see HAIR (Hypovase (prazosin), Adalat (nifedipine), indapamide, and ramipril) or BALD (bendroflumethiazide, amlodipine, lisinopril, and doxazosin) replacing orthodox monotherapy. This should be good. Patients who take one drug may …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial